Disclaimer
This website is provided for informational purposes only and does not constitute an offer to sell, or the solicitation of an offer to buy, any securities in any jurisdiction where such distribution, publication availability or use would be contrary to applicable law or regulation or would require any registration or licensing within placement or subscription or solicitation, under the United States Securities Act of 1993 as amended, or any other US state securities laws, nor should it or any part of it form the basis of, or be relied on in connection with, any contract or commitment whatsoever in any jurisdiction, including the United States.
By clicking “ACCEPT” below, you confirm your agreement to the above, and, in particular, you confirm that you qualify as a Professional Client or Eligible Counterparty under the FCA rules. Please also refer to the Terms and Conditions section on the website.
The Price of Forgetting: Valuing the future of Disease Modifying Therapies for Alzheimer’s Disease
21st July 2025
The number of dementia patients is expected to increase from 46 million to 131.5 million by 2050 as the world’s population ages. As the patient population grows, so does the economic burden, with global dementia-related costs projected to reach $2.8 trillion annually by 2030. The primary driver of dementia is Alzheimer’s disease (AD), responsible for 60-80% of cases, with the prevalence of AD doubling every five years after the age of 65.
Mortality due to AD has risen by 89% between 2000 and 2014, even as deaths from other major causes, such as heart disease and stroke, have declined. This is largely due to the progress healthcare has made towards treating most age-related diseases other than AD, for which there is no known cure.
Most approved therapies have little impact on the disease’s progression, instead focussing on managing cognitive symptoms, particularly memory loss and attention. In short, AD remains one of the last untapped frontiers in pharmaceuticals: the patient population is large, and the clinical need is urgent.
Related Posts
© 2025 S. W. Mitchell Capital LLP. All Rights Reserved. S. W. Mitchell Capital LLP is authorised and regulated by the Financial Conduct Authority. S. W. Mitchell Capital LLP is a Limited Liability Partnership registered in England no. OC312953
Registered address Princes House, 38 Jermyn Street, London, SW1Y 6DN